[ad_1]
This Wednesday, Brazilian authorities made official the death of a volunteer amid the tests of the experimental vaccine for coronavirus, developed by the University of Oxford and pharmaceutical AstraZeneca, giving rise to speculation about the security of the process and the situation of the medicine in the future.
Officially neither the University of Oxford nor AstraZeneca referred to the possibility that the 28-year-old patient, who died of Covid-19, had been inoculated with a dose of the vaccine, or a placebo. With the passing of the hours the last option took more force, although until now there is no official confirmation.
Still, after several hours of rumors, citing nearby sources to the trials, the Brazilian newspaper O’Globo and the international news agencies Bloomberg and Sputnik claimed that the young doctor was in the control group, that is to say, received placebo instead of the vaccine being tested.
The Brazilian newspaper O Globo said that the deceased volunteer was a young doctor who had been treating patients with covid-19 since March in the emergency rooms and intensive care units of two hospitals in Rio de Janeiro. He graduated from medical school last year and I was in good health before contracting the disease, family and friends told the newspaper.
The Instituto de Enseñanza e Investigación D’Or (IDOR), which is helping organize the tests in Brazil, said the independent review process “He did not raise doubts about the safety of the study and recommended that it continue.”
This is not the first incident related to phase III testing, something normal in these stages. A early september, the University of Oxford and AstraZeneca had already suspended the tests due to an adverse reaction from a participant, although the process continued a week later.
In Chile, the vaccine will be tested in conjunction with the Las Condes Clinic and the University of Chile in the coming weeks.
